| Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, ... New England Journal of Medicine 386 (1), 24-34, 2022 | 679 | 2022 |
| Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin GYH Lip, A Keshishian, S Kamble, X Pan, J Mardekian, R Horblyuk, ... Thrombosis and haemostasis 116 (11), 975-986, 2016 | 312 | 2016 |
| Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study GYH Lip, A Keshishian, X Li, M Hamilton, C Masseria, K Gupta, X Luo, ... Stroke 49 (12), 2933-2944, 2018 | 307 | 2018 |
| Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism … AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu, A Bird, D Tushabe, ... PloS one 10 (12), e0144856, 2015 | 205 | 2015 |
| Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice X Li, S Deitelzweig, A Keshishian, M Hamilton, R Horblyuk, K Gupta, ... Thrombosis and haemostasis 117 (06), 1072-1082, 2017 | 178 | 2017 |
| Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and … AT Cohen, M Hamilton, A Bird, SA Mitchell, S Li, R Horblyuk, S Batson PLoS One 11 (8), e0160064, 2016 | 70 | 2016 |
| Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label … D Cella, RJ Motzer, C Suarez, SI Blum, F Ejzykowicz, M Hamilton, ... The Lancet Oncology 23 (2), 292-303, 2022 | 48 | 2022 |
| Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in US clinical practice D Weycker, X Li, GDV Wygant, T Lee, M Hamilton, X Luo, L Vo, ... Thrombosis and haemostasis 118 (11), 1951-1961, 2018 | 43 | 2018 |
| Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation S Kachroo, M Hamilton, X Liu, X Pan, D Brixner, N Marrouche, J Biskupiak Am J Manag Care 22 (1), e1-8, 2016 | 41 | 2016 |
| Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a … X Li, A Keshishian, M Hamilton, R Horblyuk, K Gupta, X Luo, J Mardekian, ... PLoS One 13 (1), e0191722, 2018 | 39 | 2018 |
| Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies S Deitelzweig, C Farmer, X Luo, L Vo, X Li, M Hamilton, R Horblyuk, ... Current Medical Research and Opinion 33 (9), 1583-1594, 2017 | 38 | 2017 |
| Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation S Liu, X Li, Q Shi, M Hamilton, K Friend, Y Zhao, R Horblyuk, S Hede, ... Current medical research and opinion 34 (3), 415-421, 2018 | 32 | 2018 |
| Venous thromboembolism prophylaxis and clinical consequences in medically ill patients O Baser, X Liu, H Phatak, L Wang, J Mardekian, H Kawabata, D Petersel, ... American journal of therapeutics 20 (2), 132-142, 2013 | 23 | 2013 |
| Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States X Pan, TA Simon, M Hamilton, A Kuznik Journal of Thrombosis and Thrombolysis 39, 508-515, 2015 | 21 | 2015 |
| Effectiveness and safety of anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease RD Lopes, J Steffel, M Di Fusco, A Keshishian, X Luo, X Li, C Masseria, ... The American Journal of Medicine 131 (9), 1075-1085. e4, 2018 | 20 | 2018 |
| Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences T Lanitis, R Leipold, M Hamilton, D Rublee, P Quon, C Browne, AT Cohen BMC Health Services Research 17 (1), 1-14, 2017 | 20 | 2017 |
| Cost-effectiveness of apixaban versus other oral anticoagulants for the initial treatment of venous thromboembolism and prevention of recurrence T Lanitis, R Leipold, M Hamilton, D Rublee, P Quon, C Browne, AT Cohen Clinical therapeutics 38 (3), 478-493. e16, 2016 | 19 | 2016 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial. D Cella, TK Choueiri, SI Blum, F Ejzykowicz, M Hamilton, J Zhang, ... Journal of Clinical Oncology 39 (6_suppl), 285-285, 2021 | 17 | 2021 |
| Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation: assessment via a large insurance database PG Tepper, X Liu, M Hamilton, J Mardekian, W Petkun, W Tan, DE Singer Stroke 48 (6), 1487-1494, 2017 | 12 | 2017 |
| Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in … S Deitelzweig, A Keshishian, X Li, M Hamilton, C Masseria, K Gupta, ... Journal of the American College of Cardiology 71 (11S), A275-A275, 2018 | 8 | 2018 |
